{"id":1068092,"date":"2021-02-06T08:50:55","date_gmt":"2021-02-06T13:50:55","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2024-08-18T11:42:48","modified_gmt":"2024-08-18T15:42:48","slug":"bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php","title":{"rendered":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p><![CDATA[PALO ALTO, Calif., Feb.  05, 2021  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio\u2019s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan).]]><\/p>\n<p>Read more from the original source:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2021\/02\/05\/2170925\/0\/en\/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\">BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more from the original source: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068092","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068092"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068092"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068092\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}